Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

8.7%

11 terminated/withdrawn out of 126 trials

Success Rate

87.9%

+1.4% vs industry average

Late-Stage Pipeline

7%

9 trials in Phase 3/4

Results Transparency

46%

37 of 80 completed trials have results

Key Signals

15 recruiting37 with results7 terminated4 withdrawn

Enrollment Performance

Analytics

N/A
29(35.4%)
Phase 2
29(35.4%)
Phase 1
14(17.1%)
Phase 3
6(7.3%)
Phase 4
3(3.7%)
Early Phase 1
1(1.2%)
82Total
N/A(29)
Phase 2(29)
Phase 1(14)
Phase 3(6)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (126)

Showing 20 of 126 trials
NCT04675398Not ApplicableActive Not Recruiting

Adaptive Deep Brain Stimulation to Improve Motor and Gait Functions in Parkinson's Disease

Role: collaborator

NCT07424508Not ApplicableEnrolling By Invitation

Movement State-dependent Adaptive DBS for PD

Role: collaborator

NCT07024875Recruiting

Neuroimaging of Parkinson's

Role: collaborator

NCT04228172Active Not Recruiting

Genotypic Influences on Network Progression in Parkinson's Disease

Role: collaborator

NCT07103681Recruiting

White Matter Distortion and Dementia Biomarkers in Normal Pressure Hydrocephalus (NPH)

Role: collaborator

NCT04477785Recruiting

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Role: lead

NCT03883217Not ApplicableCompleted

Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease

Role: collaborator

NCT06719583Recruiting

Black and African Americans Connections to Parkinson's Disease (BLAAC PD)

Role: lead

NCT06621602Active Not Recruiting

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Role: collaborator

NCT06289582Early Phase 1Recruiting

Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

Role: collaborator

NCT07265596Phase 2Recruiting

Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

Role: lead

NCT05950906Phase 1Completed

Study to Assess PDM608 in Healthy Adult Subjects

Role: collaborator

NCT05103384Completed

Utilizing Neural Signatures and Virtual Reality to Advance DBS Programming

Role: collaborator

NCT07207057Phase 3Recruiting

Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial

Role: collaborator

NCT07142044Phase 1Recruiting

Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

Role: collaborator

NCT04598828Not ApplicableTerminated

Use of a Non-Invasive Brainstem Neuromodulation Device to Improve Neurovascular Status in Parkinson's Disease

Role: collaborator

NCT06815302Not ApplicableRecruiting

TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD

Role: collaborator

NCT05421832Completed

A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease

Role: collaborator

NCT07020026Phase 2Recruiting

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

Role: lead

NCT06193252Not ApplicableRecruiting

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Role: collaborator